# LAURA

Source: https://onco.cc/trials/laura/  
OnCo record `laura` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

For stage III lung cancers with an EGFR mutation, a targeted pill after chemoradiation cut progression by more than 80%.

## Summary

LAURA, trial NCT03521154 sponsored by AstraZeneca and reported in 2024, showed that for unresectable stage III EGFR-mutant non-small-cell lung cancer, osimertinib after chemoradiation cuts the risk of progression by more than eighty percent compared with placebo. It enrolled 216 patients, met its primary progression-free survival endpoint by blinded review with a very large effect, and led to FDA approval in September 2024, replacing durvalumab consolidation in EGFR-mutant stage III disease. OnCo links it to EGFR as a target and to osimertinib, and the result is consistent with ADAURA in showing a large EGFR inhibitor benefit after local therapy. Overall survival is immature, the trial has no independent replication, and whether indefinite osimertinib is needed or a fixed course would do is the open question. Osimertinib has its own page.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-06
- Registry id: NCT03521154
- Phase: 3
- Setting: Unresectable stage III EGFR-mutant NSCLC after chemoradiation: osimertinib until progression vs placebo
- Sponsor: AstraZeneca
- Enrolled: 216
- Result: PFS HR 0.16.
- Outcomes: Progression-free survival (BICR): Osimertinib 39.1 months vs Placebo 5.6 months, HR 0.16
- Replication: Single pivotal trial; consistent with ADAURA in showing large EGFR-TKI benefit after local therapy. OS immature.

## Sources

- ClinicalTrials.gov NCT03521154: https://clinicaltrials.gov/study/NCT03521154

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC](https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/)
- ideas: [Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models](https://onco.cc/ideas/idea-moon-closed-loop-adaptive-therapy/)
- roadmaps: [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/), [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/laura.json